Research ArticleArticle
Effect of Remission Definition on Healthcare Cost Savings Estimates for Patients with Rheumatoid Arthritis Treated with Biologic Therapies
Cheryl Barnabe, Nguyen Xuan Thanh, Arto Ohinmaa, Joanne Homik, Susan G. Barr, Liam Martin and Walter P. Maksymowych
The Journal of Rheumatology July 2014, jrheum.131449; DOI: https://doi.org/10.3899/jrheum.131449
Cheryl Barnabe
From the Department of Medicine, University of Calgary, Calgary; Department of Community Health Sciences, University of Calgary, Calgary; Institute of Health Economics, Edmonton; School of Public Health, University of Alberta, Edmonton; and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. The Alberta Biologics Pharmacosurveillance Program (ABioPharm) was supported by a grant from Alberta Health and Wellness for the study period reported. C. Barnabe, MD, MSc, FRCPC, Department of Medicine and Department of Community Health Sciences, University of Calgary; N.X. Thanh, MD, PhD, MPH, Institute of Health Economics and School of Public Health, University of Alberta; A. Ohinmaa, PhD, Institute of Health Economics and School of Public Health, University of Alberta; J. Homik, MD, MSc, FRCPC, Department of Medicine, University of Alberta; S.G. Barr, MD, MSc, FRCPC, Department of Medicine, and Department of Community Health Sciences, University of Calgary; L. Martin, MB, ChB, FRCPC, Department of Medicine, University of Calgary; W.P. Maksymowych, MB, ChB, FRCPC, Department of Medicine, University of Alberta. Address correspondence to Dr. C. Barnabe, Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1. E-mail: ccbarnab@ucalgary.ca. Accepted for publication April 17, 2014.
Nguyen Xuan Thanh
From the Department of Medicine, University of Calgary, Calgary; Department of Community Health Sciences, University of Calgary, Calgary; Institute of Health Economics, Edmonton; School of Public Health, University of Alberta, Edmonton; and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. The Alberta Biologics Pharmacosurveillance Program (ABioPharm) was supported by a grant from Alberta Health and Wellness for the study period reported. C. Barnabe, MD, MSc, FRCPC, Department of Medicine and Department of Community Health Sciences, University of Calgary; N.X. Thanh, MD, PhD, MPH, Institute of Health Economics and School of Public Health, University of Alberta; A. Ohinmaa, PhD, Institute of Health Economics and School of Public Health, University of Alberta; J. Homik, MD, MSc, FRCPC, Department of Medicine, University of Alberta; S.G. Barr, MD, MSc, FRCPC, Department of Medicine, and Department of Community Health Sciences, University of Calgary; L. Martin, MB, ChB, FRCPC, Department of Medicine, University of Calgary; W.P. Maksymowych, MB, ChB, FRCPC, Department of Medicine, University of Alberta. Address correspondence to Dr. C. Barnabe, Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1. E-mail: ccbarnab@ucalgary.ca. Accepted for publication April 17, 2014.
Arto Ohinmaa
From the Department of Medicine, University of Calgary, Calgary; Department of Community Health Sciences, University of Calgary, Calgary; Institute of Health Economics, Edmonton; School of Public Health, University of Alberta, Edmonton; and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. The Alberta Biologics Pharmacosurveillance Program (ABioPharm) was supported by a grant from Alberta Health and Wellness for the study period reported. C. Barnabe, MD, MSc, FRCPC, Department of Medicine and Department of Community Health Sciences, University of Calgary; N.X. Thanh, MD, PhD, MPH, Institute of Health Economics and School of Public Health, University of Alberta; A. Ohinmaa, PhD, Institute of Health Economics and School of Public Health, University of Alberta; J. Homik, MD, MSc, FRCPC, Department of Medicine, University of Alberta; S.G. Barr, MD, MSc, FRCPC, Department of Medicine, and Department of Community Health Sciences, University of Calgary; L. Martin, MB, ChB, FRCPC, Department of Medicine, University of Calgary; W.P. Maksymowych, MB, ChB, FRCPC, Department of Medicine, University of Alberta. Address correspondence to Dr. C. Barnabe, Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1. E-mail: ccbarnab@ucalgary.ca. Accepted for publication April 17, 2014.
Joanne Homik
From the Department of Medicine, University of Calgary, Calgary; Department of Community Health Sciences, University of Calgary, Calgary; Institute of Health Economics, Edmonton; School of Public Health, University of Alberta, Edmonton; and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. The Alberta Biologics Pharmacosurveillance Program (ABioPharm) was supported by a grant from Alberta Health and Wellness for the study period reported. C. Barnabe, MD, MSc, FRCPC, Department of Medicine and Department of Community Health Sciences, University of Calgary; N.X. Thanh, MD, PhD, MPH, Institute of Health Economics and School of Public Health, University of Alberta; A. Ohinmaa, PhD, Institute of Health Economics and School of Public Health, University of Alberta; J. Homik, MD, MSc, FRCPC, Department of Medicine, University of Alberta; S.G. Barr, MD, MSc, FRCPC, Department of Medicine, and Department of Community Health Sciences, University of Calgary; L. Martin, MB, ChB, FRCPC, Department of Medicine, University of Calgary; W.P. Maksymowych, MB, ChB, FRCPC, Department of Medicine, University of Alberta. Address correspondence to Dr. C. Barnabe, Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1. E-mail: ccbarnab@ucalgary.ca. Accepted for publication April 17, 2014.
Susan G. Barr
From the Department of Medicine, University of Calgary, Calgary; Department of Community Health Sciences, University of Calgary, Calgary; Institute of Health Economics, Edmonton; School of Public Health, University of Alberta, Edmonton; and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. The Alberta Biologics Pharmacosurveillance Program (ABioPharm) was supported by a grant from Alberta Health and Wellness for the study period reported. C. Barnabe, MD, MSc, FRCPC, Department of Medicine and Department of Community Health Sciences, University of Calgary; N.X. Thanh, MD, PhD, MPH, Institute of Health Economics and School of Public Health, University of Alberta; A. Ohinmaa, PhD, Institute of Health Economics and School of Public Health, University of Alberta; J. Homik, MD, MSc, FRCPC, Department of Medicine, University of Alberta; S.G. Barr, MD, MSc, FRCPC, Department of Medicine, and Department of Community Health Sciences, University of Calgary; L. Martin, MB, ChB, FRCPC, Department of Medicine, University of Calgary; W.P. Maksymowych, MB, ChB, FRCPC, Department of Medicine, University of Alberta. Address correspondence to Dr. C. Barnabe, Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1. E-mail: ccbarnab@ucalgary.ca. Accepted for publication April 17, 2014.
Liam Martin
From the Department of Medicine, University of Calgary, Calgary; Department of Community Health Sciences, University of Calgary, Calgary; Institute of Health Economics, Edmonton; School of Public Health, University of Alberta, Edmonton; and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. The Alberta Biologics Pharmacosurveillance Program (ABioPharm) was supported by a grant from Alberta Health and Wellness for the study period reported. C. Barnabe, MD, MSc, FRCPC, Department of Medicine and Department of Community Health Sciences, University of Calgary; N.X. Thanh, MD, PhD, MPH, Institute of Health Economics and School of Public Health, University of Alberta; A. Ohinmaa, PhD, Institute of Health Economics and School of Public Health, University of Alberta; J. Homik, MD, MSc, FRCPC, Department of Medicine, University of Alberta; S.G. Barr, MD, MSc, FRCPC, Department of Medicine, and Department of Community Health Sciences, University of Calgary; L. Martin, MB, ChB, FRCPC, Department of Medicine, University of Calgary; W.P. Maksymowych, MB, ChB, FRCPC, Department of Medicine, University of Alberta. Address correspondence to Dr. C. Barnabe, Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1. E-mail: ccbarnab@ucalgary.ca. Accepted for publication April 17, 2014.
Walter P. Maksymowych
From the Department of Medicine, University of Calgary, Calgary; Department of Community Health Sciences, University of Calgary, Calgary; Institute of Health Economics, Edmonton; School of Public Health, University of Alberta, Edmonton; and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. The Alberta Biologics Pharmacosurveillance Program (ABioPharm) was supported by a grant from Alberta Health and Wellness for the study period reported. C. Barnabe, MD, MSc, FRCPC, Department of Medicine and Department of Community Health Sciences, University of Calgary; N.X. Thanh, MD, PhD, MPH, Institute of Health Economics and School of Public Health, University of Alberta; A. Ohinmaa, PhD, Institute of Health Economics and School of Public Health, University of Alberta; J. Homik, MD, MSc, FRCPC, Department of Medicine, University of Alberta; S.G. Barr, MD, MSc, FRCPC, Department of Medicine, and Department of Community Health Sciences, University of Calgary; L. Martin, MB, ChB, FRCPC, Department of Medicine, University of Calgary; W.P. Maksymowych, MB, ChB, FRCPC, Department of Medicine, University of Alberta. Address correspondence to Dr. C. Barnabe, Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1. E-mail: ccbarnab@ucalgary.ca. Accepted for publication April 17, 2014.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Effect of Remission Definition on Healthcare Cost Savings Estimates for Patients with Rheumatoid Arthritis Treated with Biologic Therapies
Cheryl Barnabe, Nguyen Xuan Thanh, Arto Ohinmaa, Joanne Homik, Susan G. Barr, Liam Martin, Walter P. Maksymowych
The Journal of Rheumatology Jul 2014, jrheum.131449; DOI: 10.3899/jrheum.131449
Effect of Remission Definition on Healthcare Cost Savings Estimates for Patients with Rheumatoid Arthritis Treated with Biologic Therapies
Cheryl Barnabe, Nguyen Xuan Thanh, Arto Ohinmaa, Joanne Homik, Susan G. Barr, Liam Martin, Walter P. Maksymowych
The Journal of Rheumatology Jul 2014, jrheum.131449; DOI: 10.3899/jrheum.131449